{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hu Z"],"funding":["NCATS NIH HHS","NCI NIH HHS"],"pagination":["1481-1494"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5352071"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(1)"],"pubmed_abstract":["Targeting cancer stem cell (CSC) represents a promising therapeutic approach as it can potentially fight cancer at its root. The challenge is to identify a surface therapeutic oncotarget on CSC. Tissue factor (TF) is known as a common yet specific surface target for cancer cells and tumor neovasculature in several solid cancers. However, it is unknown if TF is expressed by CSCs. Here we demonstrate that TF is constitutively expressed on CD133 positive (CD133+) or CD24-CD44+ CSCs isolated from human cancer cell lines, tumor xenografts from mice and breast tumor tissues from patients. TF-targeted agents, i.e., a factor VII (fVII)-conjugated photosensitizer (fVII-PS for targeted photodynamic therapy) and fVII-IgG1Fc (Immunoconjugate or ICON for immunotherapy), can eradicate CSC via the induct"],"journal":["Oncotarget"],"pubmed_title":["Targeting tissue factor as a novel therapeutic oncotarget for eradication of cancer stem cells isolated from tumor cell lines, tumor xenografts and patients of breast, lung and ovarian cancer."],"pmcid":["PMC5352071"],"funding_grant_id":["P30 CA016058","R21 CA216697","UL1 TR001070"],"pubmed_authors":["Yu L","Hu Z","Carson WE","Xu J","McMichael E","Cheng J"],"additional_accession":[]},"is_claimable":false,"name":"Targeting tissue factor as a novel therapeutic oncotarget for eradication of cancer stem cells isolated from tumor cell lines, tumor xenografts and patients of breast, lung and ovarian cancer.","description":"Targeting cancer stem cell (CSC) represents a promising therapeutic approach as it can potentially fight cancer at its root. The challenge is to identify a surface therapeutic oncotarget on CSC. Tissue factor (TF) is known as a common yet specific surface target for cancer cells and tumor neovasculature in several solid cancers. However, it is unknown if TF is expressed by CSCs. Here we demonstrate that TF is constitutively expressed on CD133 positive (CD133+) or CD24-CD44+ CSCs isolated from human cancer cell lines, tumor xenografts from mice and breast tumor tissues from patients. TF-targeted agents, i.e., a factor VII (fVII)-conjugated photosensitizer (fVII-PS for targeted photodynamic therapy) and fVII-IgG1Fc (Immunoconjugate or ICON for immunotherapy), can eradicate CSC via the induct","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Jan","modification":"2026-05-05T08:57:59.557Z","creation":"2019-03-27T02:38:42Z"},"accession":"S-EPMC5352071","cross_references":{"pubmed":["27903969"],"doi":["10.18632/oncotarget.13644"]}}